
A federal judge in Massachusetts has blocked the U.S. Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) from enforcing restrictions that prevented Ryan White HIV/AIDS Program grantees from offering gender-affirming care to transgender patients with HIV. The ruling, delivered this week in American Academy of HIV Medicine (AAHIVM) v. HRSA, invalidates the policy and stops its reapplication for the plaintiffs—a group of HIV clinicians whose organizations represent nearly all U.S. HIV providers.
The decision stems from a September bench trial where the court found the grant conditions violated federal law and issued a permanent injunction against similar rules. The challenged language, inserted into HRSA’s fiscal year 2026 General Terms and Conditions in March, explicitly barred gender-affirming care for minors and required funding recipients to adhere to biological definitions of sex. Lambda Legal, which represented the plaintiffs, argued the restrictions conflicted with the Ryan White statute, the First Amendment, and the Fifth Amendment by forcing providers to adopt the government’s stance on gender identity.
The judge’s opinion called the restrictions “based in animus, loathing, and discrimination” and dismissed the government’s claim that the terms aligned with Congress’s intent to direct Ryan White funds exclusively toward HIV treatment. The ruling permits providers to resume gender-affirming care without risking federal funding, a service already delivered by nearly half of AAHIVM’s members, who depend on Ryan White for nearly half of their operations.
The Ryan White program annually supports nearly 602,000 clients, covering over half of all diagnosed HIV cases in the U.S. The immediate effect of the decision is the removal of the restrictions, though its long-term consequences for federally funded healthcare programs remain uncertain. Clinicians had previously faced a dilemma between complying with the rules and delivering patient-centered care, particularly for transgender individuals with HIV, whose outcomes improve when they receive gender-affirming treatment alongside HIV services.